Intravenous and Intraperitoneal Paclitaxel, Intraperitoneal Cisplatin, and Intravenous Bevacizumab for the Initial Treatment of Optimal Stage II or III Ovarian, Primary Peritoneal, and Fallopian Tube Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00588237
Recruitment Status : Completed
First Posted : January 8, 2008
Results First Posted : January 20, 2016
Last Update Posted : January 20, 2016
Genentech, Inc.
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment;   Masking: None (Open Label);   Primary Purpose: Treatment
Conditions: Ovarian Cancer
Fallopian Tube Cancer
Intervention: Drug: Paclitaxel,Cisplatin, Bevacizumab

  Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
All Patients Paclitaxel, Cisplatin, Bevacizumab

Participant Flow:   Overall Study
    All Patients
Evaluable for toxicity only                3 
Patien not treated                1 

  Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
All Patients Paclitaxel, Cisplatin, Bevacizumab

Baseline Measures
   All Patients 
Overall Participants Analyzed 
[Units: Participants]
[Units: Participants]
<=18 years   0 
Between 18 and 65 years   40 
>=65 years   2 
[Units: Participants]
Female   42 
Male   0 

  Outcome Measures

1.  Primary:   Overall Objective Response   [ Time Frame: 2 years ]

  Serious Adverse Events

  Other Adverse Events

  Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

  More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.

Results Point of Contact:  
Name/Title: Dr. Jason Konner
Organization: Memorial Sloan Kettering Cancer Center
phone: 646-888-4219

Responsible Party: Memorial Sloan Kettering Cancer Center Identifier: NCT00588237     History of Changes
Other Study ID Numbers: 06-064
First Submitted: December 22, 2007
First Posted: January 8, 2008
Results First Submitted: December 15, 2015
Results First Posted: January 20, 2016
Last Update Posted: January 20, 2016